Blood Tests for Coronary Artery Disease Evaluation
Order a lipid profile (including LDL-C), complete blood count with hemoglobin, creatinine with estimated renal function, and glycemic status (HbA1c and/or fasting plasma glucose) in all patients being evaluated for CAD. 1
Core Laboratory Panel (Class I Recommendations)
The 2024 ESC Guidelines provide the most current evidence-based approach to blood testing in CAD evaluation. These tests serve three critical purposes: identifying causes of ischemia, assessing cardiovascular risk factors, and providing prognostic information that impacts mortality and morbidity.
Essential Tests for All Patients:
- Lipid profile including LDL-C (Class I, Level A) - Critical for risk stratification and guiding statin therapy 1
- Complete blood count with hemoglobin (Class I, Level B) - Severe anemia can cause or worsen ischemia 1, 2
- Creatinine with GFR estimation (Class I, Level B) - Renal dysfunction increases CAD likelihood and worsens prognosis; also guides medication dosing 1, 2
- Glycemic assessment with HbA1c and/or fasting glucose (Class I, Level B) - Diabetes significantly impacts cardiovascular outcomes 1, 2
Additional Recommended Tests:
- Thyroid function - Should be assessed at least once in patients with suspected chronic coronary syndrome (Class I recommendation) 1
- High-sensitivity CRP and/or fibrinogen - Should be considered for additional risk stratification (Class IIa, Level B) 1
Context-Specific Testing
If Clinical Instability is Suspected:
Immediately measure high-sensitivity troponin T or I if there is any suspicion of acute coronary syndrome or CAD instability (Class I, Level A/B). 1, 2 Repeated measurements are essential to rule out myocardial necrosis. A rise or fall of at least 20% in troponin levels is consistent with myocardial infarction. 3
Important Caveats:
- When both fasting glucose and HbA1c are inconclusive, add an oral glucose tolerance test 1, 2
- Routine troponin measurement in stable outpatients with chronic CAD is not recommended - it lacks sufficient independent prognostic value to justify systematic measurement 2
- While elevated hs-CRP associates with increased event risk, evidence shows significant reporting bias, so it remains a Class IIa (not Class I) recommendation 2
Practical Algorithm:
- All patients: Lipids, CBC, creatinine/GFR, glucose/HbA1c
- First evaluation: Add thyroid function
- Consider adding: hs-CRP and/or fibrinogen for enhanced risk stratification
- If unstable symptoms: High-sensitivity troponin (repeated measurements)
- If glucose tests inconclusive: Oral glucose tolerance test
The strength of this approach lies in its dual purpose: these tests both identify treatable conditions that worsen ischemia (anemia, hyperthyroidism) and provide essential data for evidence-based secondary prevention strategies that reduce mortality.